NO20043563L - Inhibitorer av alfa L beta2 intefrinmediert celleadhesjon - Google Patents

Inhibitorer av alfa L beta2 intefrinmediert celleadhesjon

Info

Publication number
NO20043563L
NO20043563L NO20043563A NO20043563A NO20043563L NO 20043563 L NO20043563 L NO 20043563L NO 20043563 A NO20043563 A NO 20043563A NO 20043563 A NO20043563 A NO 20043563A NO 20043563 L NO20043563 L NO 20043563L
Authority
NO
Norway
Prior art keywords
beta2
inhibitors
alpha
cell adhesion
mediated cell
Prior art date
Application number
NO20043563A
Other languages
English (en)
Norwegian (no)
Inventor
Masatoshi Kakushima
Takayuki Kawaguchi
Toshiyuki Kume
Ila Sircar
Marshall Morningstar
Hidefumi Kaji
Original Assignee
Tanabe Seiyaku Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tanabe Seiyaku Co filed Critical Tanabe Seiyaku Co
Publication of NO20043563L publication Critical patent/NO20043563L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
NO20043563A 2002-02-07 2004-08-26 Inhibitorer av alfa L beta2 intefrinmediert celleadhesjon NO20043563L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35430902P 2002-02-07 2002-02-07
PCT/US2003/003449 WO2003066636A1 (en) 2002-02-07 2003-02-06 Inhibitors of alpha l beta 2 integrin mediated cell adhesion

Publications (1)

Publication Number Publication Date
NO20043563L true NO20043563L (no) 2004-11-01

Family

ID=27734354

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043563A NO20043563L (no) 2002-02-07 2004-08-26 Inhibitorer av alfa L beta2 intefrinmediert celleadhesjon

Country Status (23)

Country Link
US (1) US7375128B2 (enExample)
EP (1) EP1472257B1 (enExample)
JP (1) JP2005517016A (enExample)
KR (1) KR100625379B1 (enExample)
CN (1) CN1301255C (enExample)
AR (1) AR040068A1 (enExample)
AT (1) ATE411995T1 (enExample)
AU (1) AU2003210862B2 (enExample)
BR (1) BR0307521A (enExample)
CA (1) CA2474748A1 (enExample)
CO (1) CO5601028A2 (enExample)
DE (1) DE60324250D1 (enExample)
EC (1) ECSP045222A (enExample)
MX (1) MXPA04007643A (enExample)
MY (1) MY137878A (enExample)
NO (1) NO20043563L (enExample)
NZ (1) NZ534208A (enExample)
PE (1) PE20030899A1 (enExample)
PL (1) PL372328A1 (enExample)
RU (1) RU2315768C2 (enExample)
TW (1) TW200303200A (enExample)
WO (1) WO2003066636A1 (enExample)
ZA (1) ZA200405647B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200407324A (en) * 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
US7405234B2 (en) 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7632858B2 (en) 2002-11-15 2009-12-15 Bristol-Myers Squibb Company Open chain prolyl urea-related modulators of androgen receptor function
US7199125B2 (en) 2003-10-02 2007-04-03 Bristol-Myers Squibb Company Spiro-cyclic compounds useful as anti-inflammatory agents
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
JP2009510150A (ja) * 2005-10-06 2009-03-12 ノバルティス アクチエンゲゼルシャフト Ｌｆａ−１メディエーターとしてのテトラヒドロ−ピロリジノン化合物
CN101638429B (zh) * 2009-08-28 2012-01-25 南方医科大学 一种特异性识别细胞表面整合素α3β1的小分子肽
US8497288B2 (en) * 2011-05-09 2013-07-30 Hoffmann-La Roche Inc. Hexahydropyrroloimidazolone compounds
EP3969066B1 (en) * 2019-05-16 2025-08-20 Dispensing Dynamics International, Inc. Fragrance dispenser

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3643748A1 (de) 1986-12-20 1988-06-30 Hoechst Ag Bicylische imide, verfahren zu ihrer herstellung sowie ihre verwendung im pflanzenschutz
DE19622489A1 (de) * 1996-06-05 1997-12-11 Hoechst Ag Salze des 3-(2-(4-(4-(Amino-imino-methyl)-phenyl)-4- methyl-2,5-dioxo-imidazolidin-1-yl)-acetylamino)-3- phenyl-propionsäure-ethylesters
DK0966447T3 (da) 1997-03-03 2003-06-23 Boehringer Ingelheim Pharma Anvendelige små molekyler til behandling af betændelsessygdomme
US6214834B1 (en) * 1997-03-28 2001-04-10 Dupont Pharmaceuticals Company Integrin inhibitor prodrugs
DE69837264T2 (de) 1997-06-25 2008-01-31 Pfizer Inc. Dipeptidverbindungen, die Wachstumshormon-Sekretagoga sind
CN1185232C (zh) * 1999-10-20 2005-01-19 田边制药株式会社 αLβ2介导细胞粘连抑制剂
AU6489201A (en) * 2000-05-23 2001-12-03 Histatek Llc Modulaton of alpha-6 integrin-mediated responses

Also Published As

Publication number Publication date
NZ534208A (en) 2005-12-23
MY137878A (en) 2009-03-31
EP1472257A1 (en) 2004-11-03
TW200303200A (en) 2003-09-01
AU2003210862B2 (en) 2006-10-26
ECSP045222A (es) 2006-04-19
DE60324250D1 (de) 2008-12-04
US7375128B2 (en) 2008-05-20
AU2003210862A1 (en) 2003-09-02
BR0307521A (pt) 2004-12-28
JP2005517016A (ja) 2005-06-09
CN1628116A (zh) 2005-06-15
ATE411995T1 (de) 2008-11-15
EP1472257B1 (en) 2008-10-22
ZA200405647B (en) 2005-07-15
AR040068A1 (es) 2005-03-16
CN1301255C (zh) 2007-02-21
KR20040091625A (ko) 2004-10-28
CO5601028A2 (es) 2006-01-31
WO2003066636A1 (en) 2003-08-14
PL372328A1 (en) 2005-07-11
RU2004123219A (ru) 2006-02-10
MXPA04007643A (es) 2005-06-08
KR100625379B1 (ko) 2006-09-20
RU2315768C2 (ru) 2008-01-27
CA2474748A1 (en) 2003-08-14
PE20030899A1 (es) 2003-10-25
US20050171174A1 (en) 2005-08-04

Similar Documents

Publication Publication Date Title
NO20030885L (no) Inhibitorer av <alfa>4 styrt celleadhesjon
DK1572670T3 (da) 5-substitueret-pyrazin eller -pyridin-glucokinaseaktivatorer
PL375877A1 (en) Hydantoine derivatives and their use as tace inhibitors
DE60300604D1 (de) Druckempfindliches Klebeband
NO20043645L (no) Sykloalkylinhibitorer av kaliumkanal-funksjon
EP1578724A4 (en) INHIBITORS OF MITOTIC KINESINE
EP1581497A4 (en) INHIBITORS OF MITOTIC KINESINE
ITTO20030629A1 (it) Procedimento di realizzazione di collegamenti ad
NO20043563L (no) Inhibitorer av alfa L beta2 intefrinmediert celleadhesjon
NO20052676D0 (no) Polymorfer av bicifadin-saltsyre
DE60323571D1 (de) Wasseraktivierbarer Klebstoff
FI20020317A7 (fi) Uudet tärkkelyspohjaiset liimat
NO20031320D0 (no) System for klassifisering av havbunnsujevnhet
AU2003205452A1 (en) Bmp inhibitors for the treatment of spondyloarthropathies
DE60307471D1 (de) Hemmung
ATA7862002A (de) Wasserauslaufbatterie
ITBO20020759A1 (it) Procedimento per lo stoccaggio di informazione ad
UA7370S (uk) Комплект етикеток
UA6798S (uk) Комплект етикеток
UA6303S (uk) Комплект етикеток
UA6800S (uk) Комплект етикеток
UA6561S (uk) Комплект етикеток
UA6799S (uk) Комплект етикеток
UA7077S (uk) Комплект етикеток
UA6687S (uk) Комплект етикеток

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application